humira issu come roost readi jump back yet
remain neutral rate lower estim rare miss humira miss
below-consensu estim driven primarili eu biosimilar pressur pressur
presag previou survey work respect guidanc bracket
consensu non-gaap ep infer lower-than-expect humira revenu
instanc alreadi lower estim base check evid
enough given feel compel lower humira estim beyond
continu prefer sidelin name said dividend yield
number key drug launch tap year name upadacitinib risankizumab
think stock start look interest ceteri paribu level closer
could convinc revisit thesi
top- bottom-lin miss report top- bottom-lin miss
non-gaap ep consensu pjc total revenu
consensu pjc miss primarili driven humira versu
consensu pjc elsewher perform mix imbruvica
in-lin versu consensu pjc hcv franchis
oh guidanc revenu guid oper growth off-set
close neg fx impact impli nearli flat y/i growth vs consensu y/i
lower prior estim recal manag previous guid
double-digit ep growth meet goal
hate say told eu biosimilar eros wors guid eu
biosimilar market week manag
point worse-than-expect price competit culprit recal last june
highlight survey feedback presag worse-than-expect eros huge
shock us said forward-look implic dire nonetheless manag
move project mid-teen eu humira eros within year
eros coupl view us competit may wors
anticip think prudent lower estim go forward
whither bottom given feedback lower humira estim
meaning beyond key question cours center whether
downward revis last major reset assum
major deleteri develop think level approach
dividend yield level close name els equal could get
interest howev remain comfort sidelin
commerci regulatori clinic ip risk associ market pipelin product
fulli integr biopharmaceut compani
price et
ep discount back
year
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
page
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
row revenu
elotuzumab revenu
total ww elotuzumab revenu
row profit share
dollar except per share data
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
